ERBB2 and breast cancer: Our own and also other studies have demonstrated that miR-770-5p is downregulated in breast cancer and overexpressed miR-770-5p inhibits migration, and invasion in TNBCs where as it potentiates trastuzumab activity in HER2+ BC cells (Li et al., 2018; Noyan et al., 2019, 2021).